T3-induced hepatocyte proliferation requires β-catenin

and is protein kinase A dependent by unknown
Università degli Studi di Cagliari
DOTTORATO DI RICERCA
In TOSSICOLOGIA
Ciclo XXVI
TITOLO TESI
T3-induced hepatocyte proliferation requires β-catenin 
and is protein kinase A dependent
Settore scientifico disciplinare di afferenza
MED/04 
Presentata da: Dr. Maura Fanti
Coordinatore Dottorato: Prof. Gaetano Di Chiara
Relatore: Prof. Amedeo Columbano
Esame finale anno accademico 2012 – 2013
 

Acnowledgments
I would like to express my sincere gratitude to Prof. Amedeo Columbano and
Prof. Giovanna Maria Ledda who placed their trust in me by giving me the
opportunity to work on the project of this thesis in collaboration with 
Dr. Satdarshan Pal Singh Monga and the Department of Pathology of the
University of Pittsburgh (USA). Thanks to the joint work of the two groups,
this study has been published in the journal Hepatology 
(Fanti et al., Hepatology, Oct. 2013).
I am deeply grateful to Dr. Monga, a mentor and a friend, for his guidance in
science, motivation and enthusiasm. He has made me a more confident
person in my work and in my life. 
The experience at Pittsburgh was made special and unforgettable due to the
presence of very nice friends like Enza and Rocco Di Domenico. They
supported me as my family and always made me feel at home. I will never
forget it.
I would also like to thank my colleagues and in particular Dr. Monica Pibiri. I
really appreciate her help, advice and all her contribution of time in the
writing of this thesis.
Lastly, I would like to thank my family and my friends for all their love,
patience and encouragement during all these years.
INDEX
1
Abstract 4
Introduction 7
Aim of the study 22
Materials and Methods 24
• Animals 25
• Administration of H89, a PKA inhibitor 26
- Experimental protocol 1 26
- Experimental protocol 2 26
- Experimental protocol 3 26
• Isolation and culture of primary hepatocytes 27
• Immunohistochemistry 27
• Protein Extraction and Western Blot Analysis 29
- Antibodies 30
• Immunoprecipitation 30
• β-catenin/Tcf Transcription Reporter Assay 30
• Real-time PCR 31
• Statistics 32
Results 33
• T3-fed rats show stabilization of β-catenin and increased
expression of its targets in the liver 34
2
• β-catenin is an absolute requirement for T3 mitogenic
action in mouse liver 35
• T3 treatment induces β-catenin activity both in vitro 
and in vivo in the liver cells 37
• Mechanism of β-catenin activation brought about
by T3-treatment in vivo 38
• H89 blocks T3-induced β-catenin activation, cyclin-D1
expression and hepatocyte proliferation in mice and rats 40
Discussion 42
Figures and Legends 48
• Figure 1 49
• Figure 2 51
• Figure 3 56
• Figure 4 59
• Figure 5 62
• Figure 6 67
Bibliography 71
3
ABSTRACT
4
Thyroid  hormone  (T3),  like  many  other  ligands  of  the  steroid/thyroid
hormone  nuclear  receptor  superfamily  is  a  strong  inducer  of  liver  cell
proliferation in rats and mice. However, the molecular basis of its mitogenic
activity, which is currently unknown, must be elucidated if its use in hepatic
regenerative medicine is to be considered. F-344 rats or C57BL/6 mice were
fed a diet containing T3 for 2-7 days. In rats, administration of T3 led to an
increased cytoplasmic stabilization and nuclear translocation of  β-catenin in
pericentral  hepatocytes with concomitant  increase in cyclin-D1 expression.
T3 administration to wild-type (WT) mice  resulted in increased hepatocyte
proliferation,  however  no  mitogenic  response  in  hepatocytes  to  T3  was
evident in the hepatocyte-specific  β-catenin knockout mice (KO). In fact, T3
induced β-catenin-TCF4 reporter activity both in vitro and in vivo. Livers from
T3-treated mice demonstrated no changes in  Ctnnb1 expression, activity of
Glycogen  synthase  kinase-3β  known  to  phosphorylate  and  eventually
promote  β-catenin  degradation,  or  E-cadherin-β-catenin  association.
However,  T3 treatment increased β-catenin phosphorylation at Ser675, an
event downstream of protein kinase A (PKA). Administration of PKA inhibitor
during T3 treatment of  mice and rats as well  as in cell  culture abrogated
Ser675-β-catenin  and  simultaneously  decreased  cyclin-D1  expression  to
block hepatocyte proliferation. Conclusion: We have identified T3-mediated
hepatocyte mitogenic response to be mediated by PKA-dependent β-catenin
activation. Thus, T3 may be of therapeutic relevance to stimulate  β-catenin
signaling  to  in  turn  induce  regeneration  in  selected  cases  of  hepatic
5
insufficiency.
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INTRODUCTION
7
β-catenin  is  an  important  nuclear  effector  of  the  Wnt  signaling
pathway that is involved in the establishment of the dorsoventral axis or the
segmentation  pattern  in  embryos  [1].  Wnt  proteins  are  a  large  family  of
secreted glycoproteins which, upon receptor binding,  mediate extracellular
signaling  initiating  a  signaling  cascade,  which  results  in  activation  of  β-
catenin, the central player in the canonical Wnt pathway. In absence of Wnt
ligands, intracellular levels of β-catenin are kept low by ubiquitin-dependent
proteasomal  degradation,  set  in  motion  by a  multicomponent  degradation
complex,  consisting  of  Axin,  caseine  kinase  1α  (CK1α),  Adenomatous
polyposis coli (APC) and glycogen synthase kinase 3β (GSK3β). Binding of
Wnt proteins to the seven transmembrane (7-Tm) Frizzled (Fz) receptor and
low  density  lipoprotein  receptor-related  protein  co-receptor  5/6  (LRP5/6),
triggers  activation  of  the  canonical  Wnt  pathway.  Dishevelled  (Dvl)  is
recruited to the Frizzled receptor [2], and the Fz/Dvl complex in turn relocates
Axin to LRP5/6 [3]. Axin-bound GSK-3β and CK1 then phosphorylate LRP5/6
[4,5],  which  leads  to  inactivation  of  GSK-3β  [6].  The  absence  of
phosphorylation,  releases  β-catenin  from  the  Axin/APC/GSK3  complex,
resulting in accumulation of cytoplasmic and active β-catenin.  Although β-
catenin  lacks  a  nuclear  localization  sequence,  it  then  translocates  to  the
nucleus, through an unknown mechanism, where it acts as a transcriptional
co-activator  for  transcription factors of  the  Tcell  factor/lymphoid-enhancing
factor (TCF/LEF) family, among others [7,8]. Additional co-activators, such as
B-cell lymphoma 9 (BCL9), cAMP response element-binding protein (CREB)-
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Binding Protein (CBP)/p300 and brahmarelated gene 1 (BRG1) bind the β-
catenin-TCF  complex  and  ensure  cell-  and  tissue-specific  activation  or
suppression of transcription of numerous Wnt responsive genes [2,3, 9–12]. 
Nature Reviews Genetics 5, 691-701 (September 2004)
There  is  a  growing evidence  of  the  involvement  of  the  Wnt/β-
catenin  pathway in  liver  biology  [13].  In  adult  liver,  β-catenin is  observed
localizing mostly at the hepatocyte membrane [14], while it is present in the
cytoplasm in the biliary epithelial and endothelial cells where its role remains
unknown.  During  development  β-catenin  has  been  implicated  in  biliary
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differentiation [15–17] and transgenic mice overexpressing β-catenin resolve
intrahepatic cholestasis more efficiently than wild type controls [18]. Similarly,
recently  has  been  reported  that  Wnt2/Fz4/β-catenin  axis  seems  to  be
important in sinusoidal endothelial cell proliferation [19].
Wnt/β-catenin signaling has also been identified in hepatic stellate
cells, where has been implicated either in the maintenance of stellate cell
quiescence [20], as in stellate cell activation [21,22]. It will be highly relevant
to conclusively  address the role of  Wnt in stellate cell  biology in order to
modulate its expression as a means to inhibit hepatic fibrosis.
A key role of Wnt/β-catenin pathway was identified in adult liver
zonation. Interacting with HNF4α and Ras/MAPK/ERK signaling, β-catenin
signaling appear to dictate pericentral versus periportal gene expression in
hepatocytes, thus determining their molecular heterogeneity based on their
location within the hepatic lobule [20,23–25]. In pericentral hepatocytes, in
addition  to  membranous  localization,  β-catenin  is  expressed  both  in
cytoplasmiand nucleus, and it regulates the expression of genes that encode
for enzymes critical in ammonia and xenobiotic metabolism such as those
encoding for glutamine synthetase, (GS),  glutamate transporter (Glt1) and
cytochrome P450 family members CYP2E1 and CYP1A2. On the opposite,
the  hepatocytes  in  the  periportal  zone  show  lower  unbound,
dephosphorylated  β-catenin,  due  to  the  higher  APC protein  content,  and
express genes encoding for ammonia metabolism (such as arginase 1 and
carbamoyl-phosphate synthase). 
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β-catenin also plays a pivotal role in the maintenance of cell-cell
adhesion. In fact, it is an essential part of the adherens junctions in epithelial
cells, forming a bridge between the actin cytoskeleton and E-cadherin [26–
28]. Phosphorylation of β-catenin at a specific tyrosine residue (Y654) [29]
causes  dissociation  of  the  complex  and  subsequent  degradation  of  E-
cadherin [30]. This results in a disruption of adherens junctions and, in the
case of hepatocytes, impairment in the apical trafficking of specific proteins
[31]. Loss of cadherin function is involved in processes such as development
and  turnover  of  adult  tissues,  and  may  also  contribute  to  motility  and
metastasis in the presence of aberrant growth [32].
An important association between β-catenin and several receptor
tyrosine  kinases  has  also  been  observed  in  hepatocytes.  The  effect  of
hepatocyte  growth  factor  (HGF),  a  known  liver  mitogen,  motogen,  and
morphogen  [33],  is  mediated  through  the  binding  to  its  receptor,  Met,  a
tyrosine  kinase  ubiquitously  expressed  in  hepatocytes,  that  results  in
phosphorylation of Met which, in turn, phosphorylates β-catenin at tyrosine
residues 654 and 670, promoting its nuclear translocation and subsequent
upregulation of target  genes [34-36].  The Met/β-catenin pathways operate
synergistically to induce hepatocyte proliferation in normal and dysregulated
growth.
Active β-catenin promotes migration and cell  dedifferentiation in
nonconfluent  cells  cultured  in  the  presence  of  HGF  [37].  Opposite,  in
matrigel-induced hepatocyte re-differentiation, there is an inverse correlation
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between  Met  and  β-catenin  association  and  the  amount  of  nuclear  and
tyrosine-phosphorylated β-catenin [38]. In human tumor cell lines, β-catenin
has also been shown to be tyrosine phosphorylated upon stimulation with
HGF  [39].  β-Catenin  contributes  to  HGF-induced  hepatomegaly  in  mice
through loss of  Met/β-catenin association and subsequent  activation of β-
catenin and increased cyclin-D1 expression [40], shown to be an important
mediator of β-catenin and Met induced HCC in genetic models [41]. Further,
simultaneous activation of Met and a mutated active form of β-catenin have
been found in a subset of human hepatocellular carcinomas [42]. 
β-catenin also appears to be phosphorylated by ErbB2, a member
of the epidermal growth factor receptor (EGFR) family, whose ligand, EGF, is
another known hepatocyte mitogen. Phosphorylation of β-catenin at tyrosine-
654 [43] and constitutive tyrosine phosphorylation of β-catenin by ErbB2 has
been implicated in cancer metastasis [44,45]. EGFR has also been identified
as a transcriptional target of Wnt/β-catenin signaling [46], able to enhance
and prolong β-catenin signaling and potentiate its mitogenic effect.
The genes activated by Wnt/β-catenin signaling are diverse and
include target  genes,  such as Met,  Jagged,  gastrin,  MMP7,  survivin,  and
various FGFs [47–54], cell-cycle regulators important in proliferation, such as
cyclin-D1 [55,56], as well as oncogenes such as c-myc [57]. The majority of
Wnt  target  genes,  however,  appear  to  be  cell-type  specific  and  are  thus
regulated both temporally and contextually. In the liver, these genes include
glutamine  synthetase,  cyclin-D1,  several  cytochrome  P450s  (2e1,  1a2),
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EGFR  and  leukocyte  cell-derived  chemotaxin  2  (LECT2),  as  well  as
regucalcin or senescent marker protein-30 [46,58–64]. Interestingly, some of
the  target  genes  of  the  pathway  are  components  of  the  Wnt  signaling
pathway itself. For example, β-catenin can activate expression of repressors,
such as Axin2, Tcf1, and Dkk1 [53,65,66], or suppress pathway activators,
such as Frizzled and LPR6 [67,68],  indicating the presence of a negative
feedback loop to trigger or suppress Wnt signaling. It is still unknown whether
β-catenin  activation  in  the  absence  of  mutations  in  the  β-catenin  gene,
CTNNB1,  or  components  of  degradation  complex  such  as  AXIN1/2  will
determine  any  significant  target  gene  expression,  given  the  presence  of
several  negative  feedback  opportunities  in  this  signaling  cascade. In  the
same way, heterogeneity is evident in β-catenin activation due to mutation
sites within the exon-3 of CTNNB1, AXIN1/2 mutations as well as additional
modes in HCC such as by TGFβ or receptor tyrosine kinases, determining
variations  in  target  gene  expression,  which  eventually  result  in  a  distinct
tumor  phenotype  [69–73].  Interestingly,  Wnt/β-catenin  signaling  also  can
induce the expression of  genes which enhances and prolongs the signal,
such as LEF1, indicating the presence of a feed-forward mechanism which
can be exploited by carcinoma cells [74,75].
Despite  its  aberrant  accumulation  due  to  mutations  in
hepatocellular  cancer  (HCC),  β-catenin  is  crucial  for  cell  cycle  regulation
during  embryonic  liver  development  and  liver  regeneration  after  partial
hepatectomy  (PH)  [76,77].  In  liver  development  across  various  species,
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through  regulation  of  cell  proliferation,  differentiation,  and  maturation,  β-
catenin directs foregut endoderm specification, hepatic specification of the
foregut, and hepatic morphogenesis [77].
The Wnt/β- catenin pathway also plays a key role in postnatal liver
growth,  its  nuclear  translocation  correlating  with  an  increase  in  cell
proliferation  evident  in  livers  between  5–20  postnatal  days  [78].  Further,
conditional hepatocyte β-catenin knockout (KO) mice older than two months
[63,64], showed a significant decrease in the liver weight/body weight ratio
(15–25%), due to a basal decrease in hepatocyte proliferation as a result of
lower expression of cell cycle regulators, such as cyclin-D1, in the KO livers.
Direct  overexpression  of  β-catenin  has  also  been  shown  to
enhance  liver  growth  and  regeneration.  Transgenic  mice  overexpressing
liver-specific  wild-type  β-catenin  showed  a  15%  increase  in  liver  size
compared  to  normal  wild-type  aged-matched  controls,  due  to  increased
proliferation [46]. Liver  hyperplasia and hepatomegaly was also described in
a transgenic mouse expressing an oncogenic form of β-catenin lacking the N-
terminus,  involved  in  protein  stabilization  [79].  Another  report  described
enlarged livers shortly after adenoviral infection in a mouse strain carrying a
mutant  inducible  form  of  β-catenin  [80].  It’s  noteworthy  that  none  of  the
mouse  models  described  above  developed  spontaneous  hepatic  tumors,
demonstrating  that  mutation  of  β-  catenin  alone  is  insufficient  to  cause
tumorigenesis and suggesting that mutant-β-catenin promote tumorigenesis
only  after  a  “first  hit”,  such as  chemical  induction or  mutation  of  another
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oncogene.
During  liver  regeneration  the  steady-state  kinetics  of  β-catenin
changes dramatically. Adult liver represents a useful model to study organ
regeneration and controlled growth having the unique capacity to regenerate
after insult and loss of liver mass. A phenomenon unique to liver regeneration
is  that  repopulation  of  the  organ  occurs  almost  exclusively  through
proliferation  of  mature  cell  populations,  including  hepatocytes,  biliary
epithelial  cells,  endothelial  cells,  and  stellate  cells  [81].  Remarkably,
throughout the regenerative process, the liver still performs all the essential
functions needed for organism homeostasis, without loss of function and in
absence  of   inflammation  or  damage  to  surrounding  tissues.  The  most
common method of inducing regeneration experimentally is surgical removal
of  three  of  five  lobes  from  the  rodent  liver,  namely  2/3rd  or  partial
hepatectomy (PHx) [82]. In these conditions, the remaining two lobes grow
until complete restoration of the liver mass, approximately 7 days in the rat
[83]. 
Partial  hepatectomy triggers a series of cell  signaling pathways
and cascades that are very tightly  regulated.   One of the earliest  events,
within  30 minutes  after  PHx,  is  the  induction  of  “immediate  early  genes”,
including members of the jun, c-fos, and myc families. Transcription of these
genes are the result of rapidly activated transcription factors, preexisting in a
latent  form,   such  as  Stat3  and  NF-κB,  which  are,  in  turn,  activated  by
cytokines,  such  as  TNF-α  and  IL-6  [84].  Concomitantly  with  cytokine
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stimulation, or immediately after this period, in response to growth factors,
such as HGF and EGF [85,86] genes important for regulation of cell  cycle
entry  are  also  transcribed.  Interestingly,  fetal  markers  such  as  alpha-
fetoprotein  are  also  upregulated  during  this  time  [87],  suggesting  that
regeneration may recapitulate development to some extent.
The hallmark of liver regeneration is proliferation of adult hepatic
cell types. The first peak of DNA synthesis occurs in hepatocytes at 24 hours
in the rat and at approximately 36 hours in the mouse [83]. Hepatocyte DNA
synthesis and proliferation proceed in a zonal manner through the hepatic
lobules, from periportal to pericentral areas [88]. Rat liver is able to continue
to regenerate even after 12 sequential hepatectomies [89], which suggests
that  unlike  other  mature cells  in  the  body,  hepatocytes  are not  terminally
differentiated and can divide continuously when challenged with appropriate
stimuli [81]. Proliferating hepatocytes also produce growth factors for other
cell types, including stellate cells and endothelial cells, in a paracrine fashion.
These cells, in the rat, undergo DNA synthesis 24 hours after hepatocytes,
peaking at 48 hours after PHx [90].  Given that cyclin-D1 is a critical gene for
initiation of cell proliferation and as β-catenin is a key driver of cyclin-D1 it is
logical to assume that β-catenin plays a role in liver regeneration after PHx.
In  the  rat,  a  2.5-fold  increase  in  β-catenin  protein,  due  to
decreased  Ser  phosphorylation  and  subsequent  decreased  protein
degradation,  was  observed  during  the  early  minutes  of  liver  regeneration
induced by PHx, concomitant with translocation to the nucleus [91]. Further,
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this  initial  increase  in  β-catenin  protein  was  immediately  countered  by  a
downregulation of this pathway and activation of the destruction complex, so
that β-catenin activation after partial hepatectomy was transient, and protein
levels returned to normal 48 hours post-surgery. The early increased nuclear
localization of β-catenin during liver regeneration contributes to cyclin-D1 and
c-myc expression increase observed previously after PHx; thus, β-catenin is
a positive modulator  of  cellular  proliferation [91].  As mentioned above,  β-
catenin was also identified to be a downstream effectors of HGF, a significant
player in liver regeneration [34,36,92].
Since  conventional  β-catenin  knockout  shows  early  embryonic
lethality  [93],  the  importance  of  β-catenin  to  liver  regeneration  has  been
elucidated by several studies in which β-catenin is removed or absent from
the liver. Ablation of β-catenin transcription by administration of an antisense
oligonucleotide simultaneous with PHx resulted in a significant decrease in
liver weight/body weight ratio as late as 7 days after PHx, which was a result
of decreased hepatocyte proliferation [94]. Accordingly, conditional knockout
(KO) mice containing a hepatocyte-specific disruption of the β-catenin gene,
showed a significant and sustained decrease in liver weight/body weight ratio
(15–25%) [63,64]. Additionally, when subjected to partial hepatectomy, these
mice displayed a 2-fold decrease in the number of cells in S-phase at the
time of hepatocyte proliferation peak in wild-type (40 hours) associated to
deficient expression of cyclins involved in G1 to S transition, including cyclin-
A, D, and E [64]. Interestingly, an increase in hepatocyte proliferation was
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noted in the β-catenin-null  mice 3 days after PHx, indicative of a delayed
regenerative  onset,  and  a  second,  smaller  proliferation  peak  at  day  14,
perhaps as a compensatory event to ongoing apoptosis. This biphasic trend
in  proliferation  allows  for  delayed  but  sufficient  regeneration  of  β-catenin
knockout  livers  after  PHx [64].  Another  laboratory  utilized  liver-specific  β-
catenin  knockout  mice to  confirm a delayed onset  of  DNA synthesis  and
hepatocyte proliferation after partial hepatectomy, which is likely due to a lack
of cyclin-D1 induction [95].
The KO mice were also investigated for addressing the role of β-
catenin  in  toxicant-induced  liver  regeneration.  Sublethal  doses  of
acetaminophen  in  mice  leads  to  hepatic  injury  immediately  followed  by
enhanced  regeneration.  An  early  β-catenin  stabilization  and  not  injury
following  acetaminophen  exposure   was  identified  as  a  mechanism  of
hepatocyte proliferation [96].
While  loss  of  β-catenin  leads  to  defects  in  liver  regeneration,
activation  of  this  pathway  through  gain-of-function  mutants,  has
demonstrated the positive effect of Wnt signaling on liver regeneration.  Two
studies  have  demonstrated  the  effect  of  β-catenin  stabilization  indirectly
through ablation of  the pathway negative regulator APC gene.  In  the first
study, Apc-inactivated mice display both a clear increase in liver size and a
high  incidence  of  spontaneous  hepatocellular  cancer  [97].  In  the  second
study is reported that regeneration was accelerated in Apc+/− zebrafish after
1/3 PHx [98], while inhibition of β-catenin transcription resulted in impaired
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liver regeneration as expected, confirming the requirement for Wnt/β-catenin
signaling after liver resection. These authors further supported this finding by
demonstrating enhanced kinetics of β-catenin expression and proliferation in
APC-mutant  mice  livers  after  PHx  [98].   Finally,  it  has  also  been
demonstrated that transgenic (TG) mice expressing Ser45 mutated β-catenin
in  hepatocytes  show  a  growth  advantage  both  in  vitro  and  during  liver
regeneration through cyclin-D1 regulation. The growth advantage of S45D
TG hepatocytes after PHx may be attributed to acceleration of Met/β-catenin
dissociation, phosphorylation, and nuclear translocation 40 hours after partial
hepatectomy. 
Liver regeneration is a compensatory response to injury, in which
proliferation is essential  to restore hepatic mass and function.  In contrast,
numerous  primary  mitogens  induce  hepatocyte  proliferation  (direct
hyperplasia)  without  causing  liver  injury.  Unlike  liver  regeneration,  direct
hyperplasia, results in an excess of hepatic DNA and liver mass [99]. 
Such  mitogens include  the  peroxisome  proliferators  (PPs),  retinoic  acids
(RA),  thyroid  hormone  triiodothyronine  (T3),  and  the  halogenated
hydrocarbon 1,4-bis[2-(3,5 dichloropyridyloxy)]benzene (TCPOBOP),  which
are all ligands of nuclear receptors of the steroid/thyroid superfamily [100]. 
As  heterodimers  with  RXRα,  these  receptors  function  as  ligand-activated
transcription  factors  and  regulate  genes  involved  in  lipid  metabolism,
adipogenesis,  xenobiotic  detoxification,  and  differentiation.  Among  these
nuclear  receptor  ligands,  T3  is  particularly  interesting  since  its  mitogenic
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activity  is  associated  with  regression  of  preneoplastic  lesions  induced  by
chemical carcinogens [101,102]. 
Hepatocyte proliferation 
T3 is known to influence a variety of physiological processes, including cell
growth  and  metabolism in  mammals,  metamorphosis  in  amphibians,  and
development of  the vertebrate nervous system. Most  of  these effects  are
mediated  by  thyroid  hormone  nuclear  receptors,  (TRs),  which  act  as
transcription factors [103, 104]. Due to the ubiquitous nature of TRs, T3 has
been shown to induce proliferation in several organs including liver, kidney,
pancreas, heart  and intestine, although its effect  on liver and pancreas is
predominantly via TRβ [105].
In the liver, T3-induced proliferation lacks many early events thought to be
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critical in liver regeneration, such as activation of latent transcription factors
(AP1, NFκB) or increased expression of immediate-early transcription factors
(c-fos,  c-myc)  and  c-jun  [106,  107].  These  differences  suggest  that  the
signaling  pathways activated  by  T3  via  TRs may be different  from those
activated in liver regeneration. Interestingly, T3 has been shown to induce
cyclin-D1 expression [108]. Since cyclin-D1 is regulated by the Wnt/β-catenin
signaling in the liver during proliferative states, we asked if the effect of T3 on
cyclin-D1 expression and eventually on hepatocyte proliferation was indeed
β-catenin-dependent [108-110].
21
AIM OF THE STUDY
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Based  on  the  notion  that  cyclin-D1  is  regulated  by  the  Wnt/β-
catenin signaling, we asked if the effect of T3 on cyclin-D1 expression and
eventually hepatocyte proliferation could be β-catenin-dependent [108-111].
To  this  aim,  we  analyzed  the  role  of  β-catenin  in  T3-induced  hepatocyte
proliferation in vitro and in vivo models.
23
MATERIALS AND METHODS
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Animals
In order to evaluate the proliferative response of hepatocytes to T3 treatment,
8 week old male F-344 rats (Charles River, Milan, Italy) were maintained on a
standard  laboratory  diet  (Ditta  Mucedola,  Milan,  Italy)  or  fed  a  diet
supplemented  with  3,3′,5-Triiodo-L-thyronine (T3,  4  mg/kg  of  diet,  Sigma
Chemical Co., St Louis, MO) for 2 or 4 days. 
8-10 week old male  β-catenin KO mice or sex-matched littermate controls
obtained from Jackson Laboratories (Bar Harbor, ME) were fed a basal or a
T3-supplemented diet (4 mg/kg of diet) for 1 week. To obtain this transgenic
strain,  homozygous  floxed  β-catenin  mice  (C57BL/6  strain)  were  bred  to
Albumin-Cre mice  (C57BL/6  strain)  and the offspring carrying a floxed β-
catenin allele and albumin-Cre were again bred to the homozygous floxed β-
catenin mice. This led to a floxed allele and a floxdel-deleted (floxdel) allele of
Ctnnb1 and are referred to as Ctnnb1 loxp/loxp; Alb-Cre+/- or knockout (Ko) mice
throughout the manuscript. C57BL/6 WT mice were also fed T3 or basal diet
for 1 week to harvest livers  for addressing molecular changes. C57BL/6 WT
mice were also used in the experiments with PKA inhibitor (see below).
To label the cells, 5-bromodeoxyuridine (BrdU, 1mg/ml, Sigma Chemical Co.,
St Louis, MO) dissolved in drinking water was given to all animals throughout
the experimental period. 
In each experiment, the animals were given food and water ad libitum with a
12h  light/dark  daily  cycle.  After  sacrifice,  liver  sections  were  paraffin
embedded  for  immunoistochemistry  or  frozen  at  −80°C for  total  RNA
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isolation, and analysis.
All studies on mice and rats were performed in strict  accordance with the
Institutional Animal Use and Care Committee at the University of Pittsburgh,
the University of Cagliari and the National Institutes of Health guidelines.
Administration of H89, a PKA inhibitor
In  order  to  evaluate  the  involvement  of  PKA  pathway  in  hepatocyte
proliferation  T3-dependent,  H89 (N-[2-(p-Bromocinnamylamino)ethyl]-5-
isoquinolinesulfonamide  2HCl),  a potent  selective  inhibitor  of  cAMP
dependent protein kinase A (PKA), was tested in three different protocols:
Experimental protocol 1
3-5  month  old  male  mice  (C57BL/6  strain)  (n≥3)  were  fed  a  T3  diet
(4mg/kg/diet)  or  a  basal  diet  for  3  days.  H89  dissolved  in  saline
(200μg/100g/bw, Merck, Billerica, MA) was injected intraperitoneally (IP) 1
hour prior to T3-feeding and 2 hours before sacrifice.
Experimental protocol 2
This protocol was essentially similar to Experimental Protocol 1 except that
H89 was injected IP every 24 hours for 5 days. The animals received BrdU
dissolved in drinking water (1mg/ml) during the entire experimental period.  
Experiment protocol 3
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7  week old male F-344 rats were given a single IP dose of T3 dissolved in
saline (20μg/100g/bw) 30 minutes after H89 (200μg/100g/bw, IP). Rats were
killed 24 hours after treatment. The animals received BrdU in drinking water
(1mg/ml) during the entire experimental period. 
Isolation and culture of primary hepatocytes
Rat or mouse hepatocytes were isolated by adaptation of the calcium 2-step
collagenase perfusion technique as previously described [112].  Hepatocytes
were plated on a single layer of collagen gel and left to attach for 2 h. Six-well
cluster plates (9.8 square centimeters per plate) from Coming (Ithaca, NY)
were  used.  Unless  otherwise  specified,  10,000  hepatocytes  per  square
centimeter surface were inoculated for all  the experiments described. The
medium was changed at 2h after cells were plated.
Immunohistochemistry
Liver sections were analyzed by immunohistochemistry for β-catenin (Santa
Cruz  Biotechnology,  Santa  Cruz,  CA),  cyclin-D1  (Thermo  Scientific,
Freemont,  CA),  glutamine synthetase (GS,  Santa Cruz Biotechnology),  β-
galactosidase (Rockland Immunochemicals, Gilbertsville, PA), BrdU (Becton
Dickinson, San Jose, CA). 
Briefly,  formalin-fixed  sections  were  deparaffinized.  Endogenous  peroxide
was inactivated using 3% hydrogen peroxide (Sigma, St. Louis, MO). 
For  β-catenin,  cyclin-D1,  β-galactosidase  and  GS  staining,  slides  were
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microwaved in citrate buffer for 20 minutes followed by blocking in the blue
blocker (Shandon Lipshaw, Pittsburgh,  PA).  Sections were then incubated
with  secondary  anti-mouse  horseradish-peroxidase–conjugated  antibody
(Chemicon, Temecula, CA) for 30 minutes and the signal was detected using
the ABC Elite kit  (Vector  Laboratories,  Burlingame,  CA),  according to  the
manufacturer’s instructions. 
BrdU incorporation into nuclei was determined immunohistochemically by the
avidin-biotin-peroxidase  complex  (ABC)  method using  a  mouse  anti-BrdU
monoclonal  antibody  (Becton  Dickinson  Immunocytometry  Systems,  San
JoseÁ,  CA)  and  Vectastain  ABC  kit  (PK-4002,  Vector  Laboratories  Inc.,
Burlingame,  CA).  In  details,  formalin-fixed  sections  were  deparaffinized,
exposed  to  0.3%  hydrogen  peroxide  in  ethanol  for  10  min  to  block
endogenous  peroxidase,  treated  with  2N  HCl  for  1  hour,  incubated  with
trypsin 0.1% for 20 min and then with normal horse serum for 20 min at room
temperature.  Sections  were  then  incubated  for  2h  with  an  anti-BrdU
monoclonal  antibody,  followed  by  biotinylated  horse  anti-mouse  IgG  and
avidin-biotin peroxidase complex. Sites of peroxidase binding were detected
with  diaminobenzidine  (DAB),  and  the  sections  were  counterstained  with
hematoxylin.  A segment  of  duodenum,  an  organ  with  a  high  rate  of  cell
proliferation, was included from each animal to confirm delivery of the DNA
precursor. At least 5000 hepatocyte nuclei per animal were scored. 
The  labeling  index  (LI)  was  calculated  as  BrdU  or  cyclin-D1-positive
hepatocyte nuclei/100 nuclei. At least 5000 hepatocyte nuclei per liver were
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scored. 
Protein Extraction and Western Blot Analysis
Whole-cell lysate preparation and protein extraction from primary hepatocyte
cultures or frozen liver tissue were performed using RIPA buffer (9.1 mmol/L
dibasic sodium phosphate, 1.7 mmol/L mono- basic sodium phosphate, 150
mmol/L sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecylsulfate [pH adjusted to 7.4]) containing fresh protease and
phosphatase inhibitor cocktails (Sigma, St. Louis, MO). 
The  concentration  of  the  protein  in  the  lysates  was  determined  by  the
bicinconinic acid protein assay with bovine serum albumin as a standard.
Concentration of the samples ranged from 25 to 40 μg/μL. Aliquots of the
samples were stored at −80°C until use.
To  perform the  Western  Blot,  proteins  were  resolved  by  sodium dodecyl
sulfate–polyacrylamide gel electrophoresis analysis using the mini-PROTEIN
3-electrophoresis module assembly (BioRad, Hercules, CA) and transferred
to immobilonpolyvinylidene difluoride membranes; proteins were detected by
Super-Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL)
and visualized by autoradiography. These were scanned and densitometric
analysis  was  performed  by  NIH  Image  software  (Bethesda,  MD)  for
quantitative assessment.
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Antibodies:
The primary antibodies used were against β-catenin, GSK3β, pSer9GSK3β,
Gapdh (Santa Cruz Biotechnology, Santa Cruz, CA), pSer675β-catenin (Cell
Signaling  Technology,  Danvers,  MA),  cyclin-D1  (Thermo  Scientific),
p133CREB (Cell Signaling Technology, Danvers, MA), and  β-actin  (Sigma).
Horseradish  peroxidase–conjugated secondary antibodies were purchased
from  Chemicon.  The  proteins  were  detected  by  Super-Signal  West  Pico
Chemiluminescent  Substrate  (Pierce,  Rockford,  IL)  and  visualized  by
autoradiography. 
Immunoprecipitation
In  order  to  assess  the  association  between  E-cadherin  and  β-catenin,
immunoprecipitation was performed using 500μg of protein  extract  and β-
catenin-conjugated A/G agarose beads (Santa Cruz).  Blots were probed for
E-cadherin (BD Transduction Labs) and β-catenin (Santa Cruz).
Equal pull down was verified by probing the immunoblot for β-catenin.
β-catenin/Tcf Transcription Reporter Assay
Hepatocytes  were  plated  on  collagen  coated  six-well  plates  (Becton
Dickinson) at 300,000 cells/well  and transfected with 2.5μg of the plasmids
TOPFlash (Upstate Biotechnology, Lake Placid, NY) at 80% of confluency.
TOPFlash  has  three  copies  of  the  Tcf/Lef  sites  upstream of  a  thymidine
kinase (TK) promoter and the firefly luciferase gene. All transfections were
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performed  with  Lipofectamine2000  as  previously  described  [113]. To
normalize transfection efficiency, cells were co-transfected with 0.5μg of the
internal  control  reporter  Renilla  reniformis  luciferase  driven  under  the  TK
promoter (pRL-TK; Promega, Madison, WI). Cells have been treated with or
without 100nM of T3 in medium (Sigma). T3 was administered in two doses,
once every 24h. Forty-eight hours after transfection the cells were harvested
and  lysed  with  Passive  lysis  buffer  (Promega).  Luciferase  assay  was
performed  using  the  Dual  Luciferase  Assay  System  kit  according  to  the
manufacturer’s protocols (Promega). Relative luciferase activity was reported
as fold induction after normalization for transfection efficiency. Experiments
were repeated at least three times with 6 samples per experiment.
Real-time PCR
Total  RNA was  extracted  by  homogenizing  frozen  liver  tissue  in  Trizol®
reagent (Invitrogen, Carlsbad, CA). Two microgram of total RNA from each
sample was reverse-transcribed after DNase treatment using Super Script III
first strand kit (Invitrogen). Real-time PCR was performed on an ABI Prism
7300  Sequence  Detection  System (Applied  Biosystems,  Foster  City,  CA)
using  specific  Taqman Gene Expression  assays  (Applied  Biosystems)  for
TRα and  TRβ,  and  the  relative  expression  levels  were  calculated  after
normalization to 18S. For β-catenin gene expression, Sybr green assay was
used (Applied Biosystems) and the values were normalized to Cyclophilin
expression. 
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Statistics
Data are presented as mean ± standard error (S.E.). Comparison between
treated and control groups were performed by the ANOVA and Student’s  t
test. p<0.05 (*) was considered significant throughout the study.
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RESULTS
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T3-fed rats show stabilization of β-catenin and increased expression of
its targets in the liver. 
Previous studies have shown T3 to be a powerful liver mitogen in rats [101].
To investigate if the Wnt/β-catenin pathway is altered after T3 treatment and
contributes  towards  hepatocyte  proliferation,  we  performed
immunohistochemical studies on liver sections from rats sacrificed 2 and 4
days after T3-feeding. Normal untreated livers, referred henceforth as control
livers, show β-catenin staining only at the hepatocyte membrane (Fig. 1). T3
treatment led to increased cytoplasmic accumulation of β-catenin at day 2
followed at 4 days by enhanced cytoplasmic and nuclear localization. GS-
positivity was limited to hepatocytes in the pericentral area in controls and
T3-treated rats after 2 days; however, a modest increase in the number of
GS-positive hepatocytes was observed in the perivenular area at 4 days after
T3  treatment  (Fig.  1).  Control  livers  were  negative  for  cyclin-D1,  another
target of β-catenin and a cell cycle regulator, but increased specifically after 2
and 4 days of T3 treatment (Fig. 1). The enhanced cyclin-D1 expression in
response  to  T3  was  evident  in  pericentral  hepatocytes  at  2  days  and  it
expanded  to  additional  zones  at  4  days.  Thus,  T3  induces  β-catenin
activation in the rat liver. 
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β-catenin is an absolute requirement for T3 mitogenic action in mouse
liver. 
Based on the  above findings,  we next  asked whether  β-catenin plays  an
essential role in T3-induced mitogenesis. To this end we administered T3 to
Ctnnb1lox/lox; Alb-Cre+/− mice (KO) and wild-type littermate control mice (WT).
While  WT  mice  fed  T3  diet  for  1  week  exhibited  several  BrdU-positive
hepatocytes and hence a high LI (19.8%), almost no hepatocyte proliferation
was evident in KO mice (1.2%) (Fig. 2A, 2B). No significant difference in the
LI was observed between untreated WT or KO mice. Non-parenchymal cells
however  did  show BrdU incorporation in the hepatocyte-specific  β-catenin
KO mice in response to T3. T3 is also mitogenic for the pancreatic acinar
cells [113]. To eliminate the possibility that the discordant proliferative effects
elicited  by  T3 in  WT versus  KO mice could  be due to  differences  in  T3
metabolism or  systemic  effects,  we next  examined the  LI  of  BrdU in  the
pancreatic  acinar  cells,  which in the same animals do express normal  β-
catenin. The analysis clearly indicates that the pancreatic acinar cells in the
KO and WT mice respond robustly and comparably to T3 (Fig. 2C, 2D). 
As expected, a strong nuclear staining for cyclin-D1 was observed as early
as 4 days after T3 treatment in the hepatocytes in the WT mice; au contraire,
almost no cyclin-D1-positive hepatocytes were seen in the KO mice (Fig. 2E).
These results suggest that lack of β-catenin impairs cyclin-D1 expression and
hence affects T3-induced hepatocyte proliferation. 
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Finally, to establish whether the lack of response of KO mouse hepatocytes
to T3 could be due to down-regulation of liver thyroid hormone receptors, we
performed qRT-PCR. The results show no significant difference in the mRNA
levels of either TRα or TRβ between the WT and KO mice (Fig. 2F). This was
further validated by examining the previously published microarray analysis
of untreated WT and KO livers for thyroid receptor targets [64]. No notable
differences  in  the  expression  of  several  relevant  target  genes  of  thyroid
receptor signalling [114] were obvious representing three pooled livers for
each group. Thus it is unlikely that the impaired response of KO to T3 is due
to decreased transcriptional activation of thyroid hormone receptor genes in
the absence of β-catenin in the hepatocytes.
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T3 treatment induces β-catenin activity both in vitro and in vivo in the
liver cells. 
To  establish  whether  T3  could  directly  induce  β-catenin  activation,  we
measured luciferase activity in TOPFlash plasmid-transfected mouse and rat
primary hepatocytes as described in the methods. T3 treatment promoted
binding of  β-catenin to the TCF-binding elements leading to an increase in
the luciferase activity in primary hepatocytes in both species suggesting that
T3 can indeed activate β-catenin signaling (Fig. 3A, 3B). A control FOPFlash
reporter that contains mutated TCF-binding elements showed no luciferase
activity in absence or presence of T3 (data not shown). 
Next,  TOPGAL  reporter  mice  that  harbor  a  transgene  comprising  β-
galactosidase gene (LacZ) downstream of TCF binding elements were fed
T3-diet for 4 or 7 days. Livers sections from these mice were stained for β-
galactosidase by indirect immunostaining. While TOPGAL mice on basal diet
showed  β-galactosidase  expression  only  in  pericentral  hepatocyte  rim  as
reported  elsewhere  [23],  T3-feeding  led  to  expansion  of  β-galactosidase-
positive hepatocytes to additional few layers around the central vein, which is
suggestive of enhanced  in vivo  β-catenin activation in response to T3 (Fig.
3C).
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Mechanism of  β-catenin activation brought  about by T3-treatment  in
vivo. 
To address the mechanism by which T3 induces β-catenin activation, livers
from T3-fed mice for 4 days were assessed. qRT-PCR analysis of β-catenin
mRNA levels did not show any difference between T3-treated and untreated
mice (Fig.  4A).  While cyclin-D1 protein was consistently increased after 4
days of  T3 treatment,  no notable changes total  β-catenin or GSK3β-Ser9
(inactive  form)  were  observed  suggesting  that  β-catenin  activation
downstream of  T3  may not  be  via  canonical  Wnt  pathway (Fig.  4B).  Yet
another  pool  of  β-catenin  is  at  the  membrane  where  it  associates  to  E-
cadherin and is part of the adherens junction [115]. T3-treatment did not alter
E-cadherin-β-catenin  association  as  shown  in  a  representative
immunoprecipitation analysis (Fig. 4C). 
Futher supporting the notion the T3-induced  β-catenin activation does not
occur  via  Canonical  Wnt  pathway,  interestingly,  a  striking  increase in  the
levels of  Ser675-β-catenin was found in the T3-treated mouse livers (Fig.
4D). To verify if T3 also induced Ser675-β-catenin phosphorylation  in vitro,
primary cultures of mouse hepatocytes were treated with T3 for 30 minutes.
Analysis of whole cell lysates from these cells also showed a clear increase
in Ser675-β-catenin levels (Fig.  5A).  Phosphorylation at Ser675 has been
identified as a mechanism of β-catenin activation downstream of cyclic AMP-
dependent  protein  kinase  A (PKA)  [116,  117].  Since  CREB  is  a  known
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substrate  of  PKA  (118),  we  next  asked  if  T3  also  induced  CREB-
phosphorylation. Indeed increased pSer133-CREB was observed by western
blot analysis after 30 minutes of T3 treatment (Fig. 5A). Eventually, to directly
address if T3-induced serine phosphorylation of  β-catenin and CREB were
PKA-dependent, primary hepatocytes were treated with T3 in the presence of
H89, a small molecule inhibitor of PKA as indicated in the methods [119]. H89
prevented any increase in Ser675-β-catenin and pSer133-CREB in primary
hepatocytes in response to T3 treatment (Fig. 5A). 
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H89 blocks T3-induced  β-catenin activation, cyclin-D1 expression and
hepatocyte proliferation in mice and rats. 
To  determine  relevance  of  PKA in  T3-mediated  β-catenin  activation  and
hepatocyte  proliferation  in  vivo,  mice  were  fed  T3  diet  along  with  H89
administration as discussed in methods (see Experimental protocol 1). Total
liver lysates from such treatment show that H89 successfully abrogated T3-
mediated increase in Ser675-β-catenin in mice, which was also accompanied
by decreased levels of cyclin-D1 (Fig. 5B). Immunohistochemistry confirmed
a  significant  decrease  in  the  number  of  cyclin-D1-positive  hepatocytes  in
mice that  were  administered H89 in  addition to  T3 (Fig.  5C).  Intriguingly,
BrdU incorporation in hepatocytes in mice undergoing H89 and T3 treatment
showed a decrease as compared to T3 only fed mice, although it  missed
statistical significance due to variation in the T3-fed animals (Fig. 5D). Since
an appreciable mitogenic effect of T3 in mouse liver is achieved between 4-5
days [116], we modified the protocol by administering both T3 and H89 for 5
days (see Experimental protocol 2). This modification led to a more uniform
BrdU incorporation in control mice and an almost complete abrogation of T3-
induced hepatocyte  proliferation in  T3+H89 group of  mice (LI  was  4% in
animals receiving H89+T3 vs 16% in mice treated only with T3) (Fig. 5E).
Since  T3  also  induced  β-catenin  activation,  cyclin-D1  expression  and
hepatocyte proliferation in rat livers as shown in Fig. 1, we investigated if this
effect was via PKA. It is known that, in rats, a single dose of T3 induces a
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peak of hepatocyte proliferation 24 hours after treatment [107]. Therefore, in
this study we administered the PKA inhibitor 30 minutes prior to T3 treatment
and  sacrificed the  animals  24  hours  thereafter  (Experimental  protocol  3).
PKA inhibition almost completely prevented BrdU incorporation (LI of H89+T3
was 1.8% vs 14.0% of the T3 group) (Fig. 6A, 6B). In concordance, cyclin-D1
nuclear expression was also significantly reduced in this group of animals
(Fig.  6C,  6D).  To address the  efficacy  of  PKA inhibition in  decreasing  β-
catenin activity brought about by T3, Ser675-β-catenin levels were assessed.
Indeed, PKA blockade before T3 administration led to a significant decrease
in  Ser675-β-catenin  levels  as  assessed  at  90  minutes  after  H89  or  60
minutes after T3 treatment (Fig. 6E, 6F). 
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DISCUSSION
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The unique capability of the liver to regenerate is known since 1930s
[82]. Vast body of literature has led to an improved understanding of the cel-
lular and molecular basis of liver regeneration and it has become clear now
that tremendous redundancy exists in these processes that enable success-
ful  initiation  and  execution  of  the  liver  regeneration  process  [83].  This  is
highly relevant since liver is located strategically to perform key functions in-
dispensable to survival but at the same time is the portal of entry to toxins
and other harmful molecules through the portal circulation. Due to its critical
function in synthesis, metabolism and detoxification, and its rather vulnerable
location, liver is bestowed with a capacity to regenerate to maintain hepatic
health and homeostasis on a day-to-day basis. An overwhelming insult or any
mechanism that may impair the liver regeneration process due to acute or
chronic injury, may lead to the end stage liver disease (ESLD). The majority
of these patients with ESLD may require a liver transplant, which despite be-
ing a major advance still faces issues of donor organ scarcity and associated
morbidity. Indeed major efforts are underway to discover not only improved
transplantation technologies, but also research is underway to assess altern-
ate strategies such as cell therapy, stem cell differentiation and transplanta-
tion, tissue engineering and regenerative therapies. Thus it is of significance
to discern the signaling pathways naturally activated to enhance liver regen-
eration, which may be further stimulated through use of naturally occurring or
synthetic agents as basis for regenerative therapies [120]. 
The role  of  the Wnt/β-catenin signaling in liver regeneration has now
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been identified in multiple species ranging from zebrafish to patients and in
various models ranging from PH to toxicant-induced liver injury [91, 94-96,
98, 109]. β-catenin’s stabilization and nuclear translocation is an early event
in rat and mouse liver regeneration [110, 91, 94]. Acetaminophen-induced liv-
er regeneration also leads to β-catenin stabilization and absence of β-catenin
impaired regenerative response to an equitoxic injury in the KO mice [96].
The major basis of β-catenin’s role in liver regeneration is its ability to induce
expression of cyclin-D1, a major G1 to S phase regulator [64, 110]. Indeed
loss of β-catenin in hepatocytes led to delay in liver regeneration due to de-
creased cyclin-D1 levels [64, 95].  Conversely,  transgenic expression of N-
truncated β-catenin results in increased proliferation and hepatomegaly, while
mice expressing point mutant of β-catenin display accelerated regeneration
after PH [58, 108]. Also Wnt-1 gene therapy promoted liver regeneration after
PH due to enhanced cyclin-D1 expression [108]. Thus it appears highly relev-
ant to find a suitable modality to stimulate the Wnt signaling pathway as a
means of regenerative therapy for the liver.
In the current study,  we followed up on the observation where T3-in-
duced hepatocyte proliferation also depended solely on the induction of cyc-
lin-D1 expression [107]. T3’s ability to stimulate hepatocyte proliferation was
in fact reported in two models of impaired liver regeneration [101]. T3 stimu-
lated cyclin-D1 expression and liver regeneration in old rats subjected to PH.
It also improved BrdU LI via increased cyclin-D1 expression in rats subjected
to 90% hepatectomy. However, how T3 stimulated cyclin-D1 expression has
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remained an enigma and the current study demonstrates an imperative role
of β-catenin in this process.
In the current study, we report that the absence of β-catenin in hepato-
cytes impairs the ability of T3 to induce cyclin-D1 expression and hence T3
was unable to stimulate hepatocyte proliferation in the KO mice. Further stud-
ies demonstrate that T3 was able to cause direct activation of the β-catenin
signaling. However, this effect was not through the canonical Wnt signaling
pathway or through disruption of adherens junctions, which is yet another in-
dependent pool of β-catenin in a cell [121]. Since T3 is known to have both
genomic and non-genomic effects [122], we interrogated if T3 could impact
gene expression of CTNNB1. The genomic effects of T3 are mediated by re-
cruitment  of  thyroid  hormone receptor-associated  protein  (TRAP)/Mediator
(Med) complex and histone acetyl transferases such as p300 and p160/ster-
oid receptor coactivator to the promoters of various genes [123]. Notably, re-
cent studies have shown that intestinal epithelial cell proliferation is controlled
by thyroid hormones, and that TRα directly controls transcription of the β-
catenin gene in these cells, suggesting a direct correlation between T3, β-
catenin and a positive regulation of proliferation-controlling genes, such as
type D cyclins [124]. However, no difference in the mRNA expression of β-
catenin in the liver was observed secondary to T3-treatment,  in vivo or  in
vitro. It should be mentioned that hepatocytes are known to express higher
levels of TRβ and selective agonists for this receptor subtype are in clinical
trials  for  their  ability  to  decrease  blood lipids  through reverse  cholesterol
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transport in hepatocytes [105, 125]. Intriguingly, β-catenin phosphorylation at
Ser675 site was greatly induced by T3. This site has been shown to cause β-
catenin activation through second messenger cAMP-mediated PKA activation
[116, 117]. Indeed one of the major non-genomic effects of thyroid hormone
is via cAMP-dependent protein kinase activation [126]. Thus it appears that
T3 activates PKA to in turn induce β-catenin activation. These findings were
strengthened by inhibition of PKA through application of a small  molecule
H89, which abrogated T3-induced PKA activity leading to an impairment of
CREB  (c-AMP  response  element-binding  protein)  and  β-catenin’s  phos-
phorylation both in vitro and in vivo [118, 127]. Simultaneously, H89 adminis-
tration to T3 fed mice or rats blocked cyclin-D1 expression and resulted in
dramatically lowering hepatocyte proliferation. It was interesting to note that
T3 treatment led to a discordant  β-catenin activation,  since its two down-
stream targets were not comparably induced. While cyclin-D1 was notably
enhanced, GS was only modestly increased. The molecular basis of this ob-
servation remains obscure and may be due to the co-factor function of  β-
catenin, which may be binding to a set of specific transcription factors and
other regulatory proteins upon specific signaling. Indeed, other studies have
demonstrated such partial and discordant activation, for example in the con-
text of Lgr5-positive stem cell activation in the liver [128].
Thus T3 administration is a plausible and practical modality to induce β-
catenin signaling as a potential regenerative therapy. Additionally, selective
TRβ agonists may possess a similar property without any untoward side ef-
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fects associated with TRα activation predominantly in the heart [102, 105,
125]. This is of even greater relevance since TRβ-agonists induced regres-
sion of preneoplastic lesions in rodent livers [102]. Regenerative therapies
depend on stimulation of surviving hepatocytes in a liver after acute or chron-
ic insult and can be envisioned to be of benefit in live donor setting, small for
size syndrome, and even toxicant induced liver injury such as acetaminophen
overdose [120]. Indeed, in another study from our lab, β-catenin-positive hep-
atocytes that existed in KO mice due to leaky albumin-cre, showed growth
and survival advantage in the face of chronic liver injury brought about by ad-
ministration  of  0.1%  3,5-diethoxycarbonyl-1,4-dihydro-collidin  diet  [129].
These  β-catenin-positive hepatocytes eventually  repopulated the adult  KO
liver to maintain hepatic function and survival. Thus, stimulation of β-catenin
signaling through T3 or other analogues may be of translational relevance in
the setting of liver transplantation, cell therapy and in artificial liver devices
and hepatic tissue engineering [13].
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FIGURES AND LEGENDS
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Figure1.
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Figure1. Activation of β-catenin signaling in rat livers after T3-feeding. 
Immunostaining shows β-catenin localizing to the hepatocyte membrane in
the control livers, while it accumulates in the hepatocyte cytoplasm in T3-fed
rats at 2 days. A progressive shift of stabilization from zone I towards zone II
along with nuclear translocation of β-catenin-positive is observed at day 4 of
T3 feeding. A concomitant increase in the number of GS-positive cells around
central vein is observed at 4 days after T3. Progressive cyclin-D1 nuclear
staining is evident in zone I at 2 days, and in zone I and II at 4 days of T3
feeding as compared to the control livers. (4 rats/group were used)
50
Figura 2.
A
B
51
CD
52
EF
53
Figure 2. Lack of β-catenin in hepatocytes impairs hepatocyte prolifera-
tion and cyclin-D1 expression in response to T3 diet. 
A) Representative  microphotographs  showing  immunohistochemical
staining for BrdU in the WT and KO livers after T3-treatment for 4 days
(200X). Several BrdU-positive hepatocyte nuclei are observed in livers
of WT mice fed T3 for 4 days. KO after T3 treatment lack BrdU stain-
ing in the hepatocytes although BrdU-positive non-parenchymal cells
are evident, similar to WT livers.
B) A significant  (*p<0.05)  decrease  in  BrdU  LI  of  hepatocytes  in  KO
versus WT mice after T3 treatment. While T3 stimulated BrdU incor-
poration in the WT hepatocytes, no significant increase was evident in
KO  hepatocytes.  At  least  5000  hepatocyte  nuclei  per  liver  were
scored. The LI is expressed as number of BrdU-positive hepatocyte
nuclei/100 nuclei.  Results are expressed as mean ± standard error
(S.E.) of 3 or more mice per group. 
C) LI of pancreatic acinar cells in WT and KO mice shows no significant
difference between the two groups following treatment with T3-supple-
mented diet (4 mg/kg) for 7 days. T3 stimulated BrdU incorporation in
pancreatic acinar cells comparably and significantly (*p<0.05) in WT
and KO. At least 2000 acinar cell nuclei per pancreas were scored. LI
was expressed as number of BrdU-positive acinar cell nuclei/100 nuc-
lei and results expressed as mean ± standard error (S.E.) of 3 or more
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mice per group. 
D) Representative  microphotographs  showing  labeling  of  BrdU  in  the
pancreas of WT and KO mice treated with T3 for 4 days (200X).
E) Representative microphotographs of cyclin-D1 staining in the WT and
KO livers after 4 days of T3-feeding (200x). Absence of cyclin-D1 im-
munoreactivity in KO hepatocytes nuclei is clearly evident despite T3
feeding as compared to the WT.
F) qRT-PCR analysis of TRα and TR β expression in livers of untreated
WT and KO mice. 18S was used as endogenous control. Error bars
represent the standard error (S.E) of TaqMan RT-PCR performed in
triplicates. 
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Figure 3. T3 induces β-catenin activation in vitro and in vivo. 
A) TOPflash reporter assay shows an increase in luciferase activity 48
hours after T3 treatment of primary rat hepatocytes. A vector contain-
ing renilla luciferase was used as an internal control for transfection ef-
ficiency, and results are expressed as relative firefly/renilla luciferase
activity. The results presented are the mean ± standard error (S.E.) for
three experiments; *p < 0.05. 
B) TOPflash reporter assay shows an increase in luciferase activity 48
hours after T3 treatment of primary murine hepatocytes. A vector con-
taining renilla luciferase was used as an internal control for transfec-
tion efficiency, and results are expressed as relative firefly/renilla luci-
ferase activity. The results presented are the mean  ± standard error
(S.E.) for three experiments; *p < 0.05. 
C) IHC showing increased  β-galactosidase expression in  TOPGAL mice
fed T3 diet for 4 and 7 days. At baseline β-galactosidase expression
was detected in pericentral hepatocytes only, whereas T3 feeding led
to widening of the expression to several hepatocytes layers around the
central vein demonstrating an increase in the activity of β-catenin-TCF
complex. 
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Figure 4. T3 induced β-catenin activation via Ser675-phosphorylation. 
A) qRT-PCR analysis of β-catenin expression (normalized to cyclophilin
A) in C57BL6 mice treated with T3 for 4 days shows no change. Error
bars represent the standard error (S.E.) of TaqMan RT-PCR performed
in triplicates. 
B) Representative western blots show T3 feeding for 4 days does not
lead to a notable increase in total β-catenin when compared to basal
diet  fed mice.  However  cyclin-D1 levels  are consistently  increased.
GSK3β-Ser9 levels remain unaffected at 4 days of T3 treatment. Gap-
dh verifies equal loading. (Each lane represents a single sample).
C) Immunoprecipitation studies from three representative livers show no
change in association of β-catenin and E-cadherin in the livers of 4
days T3- versus basal diet-fed C57BL/6 mice.
D) Representative western blot shows a noteworthy increase in pSer675-
β-catenin  levels  in  4  days  T3-fed  as  compared  to  control  diet-fed
C57BL/6 mice. Gapdh verified equal loading.
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Figure 5. Blockade of Protein Kinase A impairs T3’s effect on β-catenin,
cyclin-D1 and hepatocyte proliferation in mice.
A) A representative western blot using pooled samples from three wells
per  condition  (upper  panel)  shows  increased  levels  of  pSer675-β-
catenin and pSer133-CREB in primary mouse hepatocytes after  30
minutes of T3 treatment. Inclusion of PKA inhibitor H89 (100nM) in the
media 30 minutes prior to the addition of T3 (100nM) showed a not-
able decrease in pSer675-β-catenin and pSer133-CREB levels. Dens-
itometry on the representative WB (lower panel) shows an increase in
pSer675-β-catenin and pSer133-CREB after T3 treatment, which was
blocked by H89 treatment. (I.O.D. – integrated optical density).
B) A representative western blot shows a decrease in the hepatic levels
of pSer675-β-catenin and cyclin-D1 when H89 was injected twice IP in
3-day T3 fed mice as compared to 3 day T3 only group. Gapdh verifies
equal loading. Each lane represent a single sample. 
C) A representative micrograph (200x) illustrates a decrease in the num-
ber of cyclin-D1-positive hepatocytes when H89 was injected twice to
the 3-day T3-fed mice as compared to T3 only group (upper panels).
Quantification of the cyclin-D1-positive hepatocytes shows a signific-
ant decrease in positive cells in H89+T3 as compared to T3 only group
(*p<0.05) (lower panel). Three or more mice /group were used.
D) BrdU  LI was after  day of T3-feeding was significantly increased as
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compared to basal diet or H89 treatment (*p<0.05). BrdU LI was lower
in livers  when H89 was injected twice to the 3-day T3-fed mice as
compared to T3 only group, however it missed statistical significance
due to variation in the number of BrdU-positive hepatocytes in the T3
only group. Three or more mice /group were used.
E) A representative microphotographs (200x) illustrates a noteworthy in-
crease in BrdU uptake by the hepatocytes in mice after 5 days of T3
feeding, which was dramatically decreased in animals simultaneously
administered H89 IP every  24 hours  (left  panels).  Quantification of
BrdU positive hepatocytes shows a significant (*p<0.05) decrease in
the LI in T3+H89 group as compared to T3 only. Three mice/group
were used.
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Figure 6. Blockade of Protein Kinase A impairs T3’s effect on β-catenin,
cyclin-D1 and hepatocyte proliferation in rats
A) Representative microphotographs (200x) illustrate the effect of H89 on
T3-induced  rat  hepatocyte  proliferation  by  BrdU immunohistochem-
istry. H89 was given 1 hour prior to a single dose of T3 (20 ug/100 g)
and the rats were sacrificed 24 hours later. 
B) Quantification of BrdU positive hepatocytes in A shows a significant
(*p<0.05) increase in the LI after T3 treatment, which was significantly
abrogated in the presence of H89 (*p<0.05).  Four to five rats/group
were used.
C) Representative microphotographs (200x) show increased nuclear cyc-
lin-D1  expression  in  hepatocyte  following  a  single  injection  of  T3,
which was decreased in the group that simultaneously received H89
as well. 
D) Quantification of cyclin-D1-positive hepatocytes to calculate LI shows
a significant increase after T3 treatment (*p<0.05), which was reduced
significantly  in  the  H89  pretreatment  group  (*p<0.05).  Four  to  five
rats/group were used.
E) A representative western blot shows the effect of H89 on T3-induced
Ser675-β-catenin levels in rat liver. Gapdh depicts protein loading. 
F) Densitometric analysis of E (Ser675-β-catenin normalized to Gapdh)
using the ImageJ software shows a significant (*p<0.05) decrease in
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Ser675-β-catenin levels  in  T3+H89 as  compared to  T3 only  group.
(I.O.D. – integrated optical density).
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